Non-Nucleoside Reverse Transcriptase Inhibitors: The NNRTI Boom
نویسندگان
چکیده
منابع مشابه
Non-nucleoside reverse transcriptase inhibitors
(NNRTIs) are promising drugs for the treatment of HIV when used in combination with other antiHIV drugs such as nucleoside reverse transcriptase (RT) inhibitors and protease inhibitors. The first generation of NNRTIs have, however, suffered from the rapid development of resistance. This review discusses the properties of the FDAapproved NNRTI drugs and focuses on the recent efforts being made t...
متن کاملNucleoside Reverse Transcriptase Inhibitors
Although the incidence of HIV infection among women is increasing, the proportion of women in clinical trials that evaluate interventions for the treatment of HIV infection and its complications has historically been lower than the proportion of women in the HIV/AIDS patient population. Therefore, most knowledge about the efficacy of antiretroviral drugs and the adverse reactions associated wit...
متن کاملDrug design strategies using non nucleoside reverse transcriptase inhibitors (NNRTI): current challenges and future perspectives
The emerging drug resistance towards anti-HIV compounds attracted the attention of scientific community. Development of potent anti-HIV therapy using non-nucleoside reverse transcriptase inhibitors (NNRTIs) known to be a promising strategy. Although NNRTIs has great importance in HIV-1 treatment and prevention but their mechanism of action has not yet been studied in detail. The present review ...
متن کاملHIV Nucleoside Reverse Transcriptase Inhibitors
Currently, 16 antiretroviral drugs are approved for treatment of HIV infection. However, even the best currently available regimens pose challenges with regard to adherence, toxicity, antiviral activity, and resistance. New drug development thus confronts the need for improved convenience and tolerability, reduced toxicity, and improved activity against both wild-type and drug-resistant viruses...
متن کاملNucleoside Reverse Transcriptase Inhibitors (NRTIS)
substantial progress continues to be made in the arena of antiretroviral drug development. prn is again proud to present its annual review of the experimental agents to watch for in the coming months and years. This year’s review is based on a lecture by Dr. Roy M. Gulick, a longtime friend of prn, and no stranger to the antiretroviral development pipeline. To date, twenty-two antiretrovirals h...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Antiviral Chemistry and Chemotherapy
سال: 1999
ISSN: 2040-2066,2040-2066
DOI: 10.1177/095632029901000601